OptimizeRx Corp. (NASDAQ:OPRX) Receives $17.57 Average PT from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $17.5714.

Several research firms recently commented on OPRX. Zacks Research raised OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, March 13th. Stephens dropped their target price on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. B. Riley Financial reiterated a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Finally, Stifel Nicolaus lowered their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, March 6th.

Hedge Funds Weigh In On OptimizeRx

Several large investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in shares of OptimizeRx during the second quarter worth about $44,000. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in OptimizeRx during the 4th quarter worth approximately $62,000. USA Financial Formulas purchased a new stake in OptimizeRx during the 3rd quarter worth approximately $131,000. Finally, ExodusPoint Capital Management LP acquired a new stake in OptimizeRx during the 4th quarter worth approximately $150,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Stock Performance

OPRX opened at $6.56 on Friday. The firm’s fifty day simple moving average is $8.08 and its two-hundred day simple moving average is $13.17. OptimizeRx has a 52-week low of $5.54 and a 52-week high of $22.25. The company has a market cap of $123.08 million, a price-to-earnings ratio of 25.23 and a beta of 1.28. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. Equities analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

OptimizeRx declared that its board has authorized a share repurchase program on Thursday, March 5th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its stock is undervalued.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.